Acute myeloid leukemia (AML) is a heterogeneous disease with limited therapeutic options. A new study identifies leukocyte immunoglobulin-like receptor 3 (LILRB3) as a marker of monocytic AML, with the ability to modulate NF-κB signaling and to promote survival and immune evasion. Blockade of LILRB3 signaling could provide a novel therapeutic strategy in monocytic AML.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CLPs-miR-103a-2-5p inhibits proliferation and promotes cell apoptosis in AML cells by targeting LILRB3 and Nrf2/HO-1 axis, regulating CD8 + T cell response
Journal of Translational Medicine Open Access 14 March 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Witkowski, M. T., Lasry, A., Carroll, W. L. & Aifantis, I. Trends Cancer 5, 604–618 (2019).
Wu, G. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00262-0 (2021).
Zhang, J. et al. J. Leukoc. Biol. 102, 351–360 (2017).
Godal, R. et al. Biol. Blood Marrow Transplant. 16, 612–621 (2010).
Zhang, Y. et al. Mol. Med. Rep. 5, 910–916 (2012).
Deng, M. et al. Nature 562, 605–609 (2018).
Carosella, E. D., Rouas-Freiss, N., Roux, D. T.-L., Moreau, P. & LeMaoult, J. in Advances in Immunology Vol. 127 (ed. Alt, F. W.) 33–144 (Academic Press, 2015).
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. & Kroemer, G. Nat. Rev. Immunol. 17, 97–111 (2017).
Trowbridge, J. J. & Starczynowski, D. T. J. Exp. Med. 218, e20201544 (2021).
Baldridge, M. T., King, K. Y. & Goodell, M. A. Trends Immunol. 32, 57–65 (2011).
Carey, A. et al. Cell Rep. 18, 3204–3218 (2017).
Cai, Z. et al. Cell Stem Cell 23, 833–849.e5 (2018).
Hormaechea-Agulla, D. et al. Cell Stem Cell 28, 1428–1442.e6 (2021).
Grants, J. M. et al. Blood 135, 2235–2251 (2020).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Lasry, A., Aifantis, I. LILRB3 as a regulator of AML survival. Nat Cancer 2, 1122–1123 (2021). https://doi.org/10.1038/s43018-021-00285-7
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-021-00285-7
This article is cited by
-
CLPs-miR-103a-2-5p inhibits proliferation and promotes cell apoptosis in AML cells by targeting LILRB3 and Nrf2/HO-1 axis, regulating CD8 + T cell response
Journal of Translational Medicine (2024)
